<?xml version="1.1" encoding="UTF-8" standalone="yes"?><xml><head><creation_date>D:20100204150829+01'00'</creation_date><modification_date>D:20100204150831+01'00'</modification_date><initial_authorization>False</initial_authorization><pdf_file>EU-1-00-129_h_dec_8.pdf</pdf_file></head><body><section><header>en  
   en</header></section><section><header>en</header></section><section><header>en  
   en</header><p>european commission</p><p>brussels, 29.1.2010 c(2010)706</p></section><section><header>commission decision of 29.1.2010 
 on the renewal of the marketing authorisation for the medicinal product for human 
 use &quot;azopt - brinzolamide&quot;, granted by decision c(2000)576</header><p>(only the english text is authentic)</p></section><section><header>en</header><p>2</p></section><section><header>en</header></section><section><header>commission decision of 29.1.2010 
 on the renewal of the marketing authorisation for the medicinal product for human 
 use &quot;azopt - brinzolamide&quot;, granted by decision c(2000)576 
 (text with eea relevance)</header><p>the european commission, having regard to the treaty on the functioning of the european union, 
 having regard to regulation (ec) no 726/2004 of the european parliament and of the 
 council of 31 march 2004 laying down community procedures for the authorisation and 
 supervision of medicinal products for human and veterinary use and establishing a 
 european medicines agency
 1, and in particular article 10(2) thereof, having regard to the application submitted by alcon laboratories (uk) ltd., on 16 june 
 2009, under article 14(2) of regulation (ec) no 726/2004 with a view to the renewal of 
 the marketing authorisation for the medicinal product &quot;azopt - brinzolamide&quot; 
 having regard to the opinion of the european medicines agency, formulated by the 
 committee for medicinal products for human use on 28 june 2009, 
 having regard to directive 2001/83/ec of the european parliament and of the council of 
 6 november 2001 on the community code relating to medicinal products for human use
 2, and in particular article 61(3) thereof, 
 whereas: 
 (1)</p><p>on the basis of a re-evaluation by the agency of the risk-benefit balance 
 following the consideration of a consolidated file, it appears that the medicinal 
 product &quot;azopt - brinzolamide&quot;, entered in the community register of medicinal 
 products under number(s) eu/1/00/129/001-003 and authorised by commission 
 decision c(2000)576 of 9 march 2000, complies with the requirements set out in 
 directive 2001/83/ec of the european parliament and of the council of 6 
 november 2001 on the community code relating to medicinal products for 
 human use
 3. (2)</p><p>the marketing authorisation which expires on 10 march 2010 should therefore be 
 renewed. 
 (3)</p><p>alcon laboratories (uk) ltd. submitted, under article 61(3) of directive 
 2001/83/ec, a notification(s) for changes to an aspect of the labelling or the</p><p>
 1 oj l 136, 30.4.2004, p. 1. 2 oj l 311, 28.11.2001, p. 67. 3 oj l 311, 28.11.2001, p. 67.</p></section><section><header>en</header><p>3</p></section><section><header>en</header><p>package leaflet, which has (have) not yet been included in decision c(2000)576 of 9 march 2000. 
 (4)</p><p>the measures provided for in this decision are in accordance with the opinion of 
 the standing committee on medicinal products for human use, 
 has adopted this decision: 
 article 1 the marketing authorisation granted by decision c(2000)576 of 9 march 2000 which expires on 10 march 2010 is renewed. 
 article 2 decision c(2000)576 is amended as follows: 1) the following list of notifications for changes to an aspect of the labelling or the 
 package leaflet is added to the updated marketing authorisation; 
 application number 
 annex (eu numbers affected) 
 emea/h/c/267/n/33 
 iiiab (eu/1/00/129/001-003)</p><p>
 2) annex i is replaced by the text set out in annex i to this decision; 
 3) annex ii is replaced by the text set out in annex ii to this decision; 
 4) annex iii is replaced by the text set out in annex iii to this decision. 
 article 3 this decision is addressed to alcon laboratories (uk) ltd., pentagon park, boundary way, hemel hempstead, herts hp2 7ud, united kingdom. 
 done at brussels, 29.1.2010 
 for the commission heinz zourek 
 director-general</p></section></body></xml>